Yahoo
OTC Markets OTCID USD

Altamira Therapeutics Ltd. (CYTOF)

0.0710 -0.0320 (-31.07%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for CYTOF
  • Previous Close 0.1030
  • Open 0.0800
  • Bid 0.0740 x 1500000
  • Ask 0.1250 x 2543000
  • Day's Range 0.0800 - 0.0800
  • 52 Week Range 0.0500 - 0.1480
  • Volume 3,843
  • Avg. Volume 4,125
  • Market Cap (intraday) 405,798
  • Beta (5Y Monthly) 2.78
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1900
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

altamiratherapeutics.com

11

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CYTOF
22.83%
S&P 500 (^GSPC)
10.73%

1-Year Return

CYTOF
24.47%
S&P 500 (^GSPC)
11.11%

3-Year Return

CYTOF
97.68%
S&P 500 (^GSPC)
81.91%

5-Year Return

CYTOF
99.99%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY19
Revenue --
Earnings --
Profit Margin 0.00%

Q3

FY18

Q4

FY18

Q1

FY19

Q2

FY19

-3M
-2M
-1M
0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -45.75%

  • Return on Equity (ttm)

    -108.79%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -5.65M

  • Diluted EPS (ttm)

    -1.1900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.75k

  • Total Debt/Equity (mrq)

    19.39%

  • Levered Free Cash Flow (ttm)

    -2.1M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: